Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Andy Rawstron, PhD, Talha Munir, Kristian Brock, MSc, BSc, Nichola Webster, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Sophie Cramp, MSc, BSc, Rebecca Bishop, BSc, Surita Dalal, PhD, Ruth M De Tute, BSc,MSc, Oonagh Sheehy, Andrew Pettitt, FRCPath, PhD, Christopher P. Fox, MD PhD, Stephen Devereux, PhD, Christopher Fegan, MD, Donald MacDonald, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 181.

https://doi.org/10.1182/blood-2018-181

Published: 2018

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD

Blood (2017) 130 (Supplement 1): 904.

https://doi.org/10.1182/blood.V130.Suppl_1.904.904

Published: 2017

Journal Articles

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3004.

https://doi.org/10.1182/blood.V130.Suppl_1.3004.3004

Published: 2017

Journal Articles

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Talha Munir, Peter Hillmen, MBChB, PhD, Lucy McParland, Dena Cohen, Anna Hockaday, Jamie Oughton, Fabrizio Messina, David Phillips, Jeffrey R. Neilson, FRCP,FRCPath, Nicholas Pemberton, Shankara Paneesha, MD MRCP, FRCPath, Ben Kennedy, MBChB, FRCP, FRCPath, Andy Rawstron, PhD

Blood (2017) 130 (Supplement 1): 3013.

https://doi.org/10.1182/blood.V130.Suppl_1.3013.3013

Published: 2017

Journal Articles

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Talha Munir, Peter Hillmen, MBChB, PhD, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz-Vicente, Francesca Yates, PhD, Surita Dalal, PhD, Ruth M de Tute, PhD FRCPath, Chris P Fox, Donald Macdonald, Christopher Fegan, MD, Adrian Bloor, Anna Schuh, MD PhD, Gina Doody

Blood (2017) 130 (Supplement 1): 3014.

https://doi.org/10.1182/blood.V130.Suppl_1.3014.3014

Published: 2017

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

Journal Articles

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Ruth M de Tute, Anna Baginska, Christopher Parrish, MD, Shameem Mahmood, MRCP. FRCPath, Andy Rawstron, PhD, Julian D Gillmore, MD FRCP, Helen J Lachmann, MD FRCP, Philip N Hawkins, Roger G Owen, MD, Ashutosh Wechalekar, Dr

Blood (2014) 124 (21): 2073.

https://doi.org/10.1182/blood.V124.21.2073.2073

Published: 2014

Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 3378.

https://doi.org/10.1182/blood.V122.21.3378.3378

Published: 2013

Journal Articles

What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.

Anna Vardi, Antonis Dagklis, Lydia Scarfò, Diane F. Jelinek, PhD, Darren J Newton, Chi Doughty, PhD, Julia Almeida, Arancha Rodriguez-Caballero, Sallie D. Allgood, MS, Mark C. Lanasa, MD, PhD, Agostino Cortelezzi, MD, Ester M Orlandi, Silvio Veronese, Marco Montillo, MD, Andy Rawstron, PhD, Tait D. Shanafelt, MD, Alberto Orfao, Kostas Stamatopoulos, Paolo Ghia

Blood (2012) 120 (21): 2883.

https://doi.org/10.1182/blood.V120.21.2883.2883

Published: 2012

Journal Articles

Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications

Abraham M Varghese, Andy Rawstron, PhD, Gina M Doody, PhD, Darren J Newton, Reuben Tooze, PhD, Peter Hillmen, MBChB, PhD

Blood (2012) 120 (21): 3899.

https://doi.org/10.1182/blood.V120.21.3899.3899

Published: 2012

Journal Articles

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

Ruth M de Tute, Eve Roman, Andrew Jack, PhD, MB, Roger G Owen, MD, Andy Rawstron, PhD

Blood (2011) 118 (21): 2652.

https://doi.org/10.1182/blood.V118.21.2652.2652

Published: 2011

Journal Articles

In Vitro Generation of “Long-Lived” Human Plasma Cells

Sophie Stephenson, Msc, Mario Cocco, PhD, Ruth deTute, Msc, Andy Rawstron, PhD, Gina Doody, PhD, Reuben Tooze, PhD

Blood (2011) 118 (21): 2187.

https://doi.org/10.1182/blood.V118.21.2187.2187

Published: 2011

Journal Articles

Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis

Krzysztof Jamroziak, Janusz Szemraj, PhD, Andy Rawstron, PhD, Zofia Szemraj-Rogucka, MD, Olga Grzybowska-Izydorczyk, MD, PhD, Krzysztof Giannopoulos, MD, PhD, Gabriele Buda, M.D., PhD, Alessandro Martino, PhD, Dorota Jesionek-Kupnicka, MD, PhD, Ida Franiak-Pietryga, PhD, Magdalena Piotrowska, MD, Tadeusz Robak, MD, PhD

Blood (2011) 118 (21): 4585.

https://doi.org/10.1182/blood.V118.21.4585.4585

Published: 2011

Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 922.

https://doi.org/10.1182/blood.V116.21.922.922

Published: 2010

Journal Articles

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A. Follows, Donald Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David G. Oscier, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Andy Rawstron, PhD, Christopher F.E. Pocock, MD, PhD

Blood (2010) 116 (21): 697.

https://doi.org/10.1182/blood.V116.21.697.697

Published: 2010

Journal Articles

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, MD, PhD, Andy Rawstron, PhD, Walter M Gregory, Alex Smith, Emma Skinner, BSc, Anne Critchley, MB, BS, Donald Milligan, MD, FRCP, FRCPath, Claire E. Dearden, MD, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 60.

https://doi.org/10.1182/blood.V116.21.60.60

Published: 2010

Journal Articles

Reguatory T-Cell Subsets Demonstrate Quantitative Differences but Not Functional Abnormalities in Patients with Multiple Myeloma (MM) Compared with Healthy Controls.

Sylvia Feyler, MD, Marie von Lilienfeld-Toal, MD, Lee Marles, PhD, Andy Rawstron, PhD, Roger G. Owen, MD, John Ashcroft, PhD, Gordon Cook, PhD

Blood (2007) 110 (11): 3511.

https://doi.org/10.1182/blood.V110.11.3511.3511

Published: 2007

Journal Articles

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Peter Hillmen, MBChB, PhD, Christopher Pocock, MB, BS, PhD, Dena Cohen, MSc, Kim Cocks, MSc, Hazem A. Sayala, MB, BCh, Andy Rawstron, PhD, Daniel B. Kennedy, MB, ChB, Christopher Fegan, MB, BS, Don W. Milligan, MB, ChB, Claire Dearden, MB, BS, Alexandra Smith, BSc, Emma Lindop, BSc, Andrew R. Pettitt, MB, BChir, PhD

Blood (2007) 110 (11): 752.

https://doi.org/10.1182/blood.V110.11.752.752

Published: 2007

Journal Articles

Genomics Analysis of Freshly-Purified Human Marrow Stromal Cells (MSCs): Comparison with Hematopoietic Lineage Cells and Culture-Expanded MSCs.

Elena A. Jones, PhD, Sally E. Kinsey, MD, Anne English, FIBMS, Sarah Field, BSc, Andy Rawstron, PhD, Richard A. Jones, PhD, Liz Strazsynski, BSc, Stephen Rundlett, PhD, Selina Jain, Robert Deans, PhD, Paul Emery, MD, Frederique Ponchel, PhD, Dennis McGonagle, PhD

Blood (2006) 108 (11): 2570.

https://doi.org/10.1182/blood.V108.11.2570.2570

Published: 2006

NARROW

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.

Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

In Vitro Generation of “Long-Lived” Human Plasma Cells

Polymorphisms of Mir-34b/c, Mir-146a and Mir-196a-2 and Predisposition to Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Reguatory T-Cell Subsets Demonstrate Quantitative Differences but Not Functional Abnormalities in Patients with Multiple Myeloma (MM) Compared with Healthy Controls.

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Genomics Analysis of Freshly-Purified Human Marrow Stromal Cells (MSCs): Comparison with Hematopoietic Lineage Cells and Culture-Expanded MSCs.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only